AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Supernus Pharmaceuticals, Inc.
Video analysis: SUPN
All videosNo video analysis for this stock yet. Request one from our team.
News: SUPN
Supernus Pharmaceuticals to Participate in September Investor Conferences
ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following September investor conferences:
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
ROCKVILLE, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Professional snowboarder, Chloe Kim, is partnering with Supernus Pharmaceuticals as a compensated ambassador to discuss her journey with attention-deficit/hyperactivity disorder (ADHD) and her treatment plan with Qelbree (viloxazine extended-release capsules), a once-daily, non-stimulant medication for patients 6 years and older. Designed for flexible once-a-day routine integration, Qelbree offers 24-hour medication exposure, no evidence of abuse potential, and versatile administration options, including the ability to be sprinkled and taken at any time of day (either morning or night). Through this partnership, Chloe Kim will open up about her own diagnosis to challenge misconceptions about ADHD. By sharing her lived experience, she will encourage others to advocate for their health and initiate collaborative conversations with their doctors about a potential treatment plan.
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) to Indivior Pharmaceuticals, Inc. for
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) to Indivior Pharmaceuticals, Inc. for 1.5401 common shares of Indivior for each share of Supernus.Halper Sadeh encourages Supernus shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.The investigation con.
BlackRock Inc. Purchases New Position in Supernus Pharmaceuticals, Inc. $SUPN
BlackRock Inc. purchased a new position in Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 9,350,046 shares of the specialty pharmaceutical company's stock, valued at approximately $434,871,000. BlackRock Inc. owned approximately 16.08% of
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?
Investors need to pay close attention to SUPN stock based on the movements in the options market lately.
Critical Survey: Vectura Group (OTCMKTS:VEGPF) versus Supernus Pharmaceuticals (NASDAQ:SUPN)
Supernus Pharmaceuticals (NASDAQ: SUPN - Get Free Report) and Vectura Group (OTCMKTS:VEGPF - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership. Risk and Volatility Supernus Pharmaceuticals has a beta
Allworth Financial LP Invests $2.36 Million in Supernus Pharmaceuticals, Inc. $SUPN
Allworth Financial LP acquired a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 50,669 shares of the specialty pharmaceutical company's stock, valued at approximately $2,357,000. Allworth Financial LP owned about 0.09%
Similar companies
-
HUTCHMED (China) Limited
HCM
·
NASDAQ
Compare
-
Perrigo Company plc
PRGO
·
New York Stock Exchange
Compare
-
Xenon Pharmaceuticals Inc.
XENE
·
NASDAQ
Compare
-
Indivior Pharmaceuticals Inc
INDV
·
NASDAQ
Compare
-
Bausch Health Companies Inc.
BHC
·
New York Stock Exchange
Compare
-
Amneal Pharmaceuticals, Inc.
AMRX
·
NASDAQ
Compare